UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000047879 |
|---|---|
| Receipt number | R000054581 |
| Scientific Title | Effects of consumption of the test food on the postprandial blood GLP-1 in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, crossover comparison trial |
| Date of disclosure of the study information | 2022/05/27 |
| Last modified on | 2022/12/23 09:44:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of consumption of the test food on the postprandial blood GLP-1 in healthy Japanese subjects
Acronym
Effects of consumption of the test food on the postprandial blood GLP-1 in healthy Japanese subjects
Scientific Title
Effects of consumption of the test food on the postprandial blood GLP-1 in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, crossover comparison trial
Scientific Title:Acronym
Effects of consumption of the test food on the postprandial blood GLP-1 in healthy Japanese subjects
Region
| Japan |
Condition
Condition
Healthy Japanese subjects
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To verify the effects of consumption of the test food of the postprandial blood GLP-1 and the glucose metabolism in healthy Japanese subjects
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
1. The incremental area under the curve (IAUC) of the postprandial blood glucagon-like peptide-1 (GLP-1)
Key secondary outcomes
1. IAUC of peptide YY (PYY), glucose, and insulin in the postprandial blood
2. The postprandial maximum blood concentration (Cmax) of GLP-1, PYY, glucose, and insulin
3. The blood GLP-1 before consumption of the test food and 15, 30, 60, and 120 minutes after consumption of the carbohydrate load
4. The blood PYY before consumption of the test food and 15, 30, 60, and 120 minutes after consumption of the carbohydrate load
5. The blood glucose before consumption of the test food and 15, 30, 60, and 120 minutes after consumption of the carbohydrate load
6. The blood insulin before consumption of the test food and 15, 30, 60, and 120 minutes after consumption of the carbohydrate load
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Institution is not considered as adjustment factor.
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Period I: Capsule containing 10-hydroxy-cis-12-octadecenoic acid (HYA)
Period II: Placebo
Carbohydrate load: Trelan-G 75 g
After taking blood samples prior to ingesting test foods, take three active or placebo capsules with approximately 200 mL of water. Then, take the carbohydrate load within 10 minutes.
*The intervention sequence is Period I to Period II, and each food is single ingestion.
*Washout period is for one week and more
Interventions/Control_2
Period I: Placebo
Period II: Capsule containing HYA
Carbohydrate load: Trelan-G 75 g
After taking blood samples prior to ingesting test foods, take three active or placebo capsules with approximately 200 mL of water. Then, take the carbohydrate load within 10 minutes.
*The intervention sequence is Period I to Period II, and each food is single ingestion.
*Washout period is for one week and more
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Japanese
2. Men or women
3. Adults
4. Healthy subjects
5. Subjects whose BMI are 23 kg/m2 or more and less than 30 kg/m2
Key exclusion criteria
1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Subjects who currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Subjects who have food allergies and/or food intolerances. Particularly, subjects who have lactose intolerance.
5. Subjects who have abnormal glucose tolerance
6. Subjects who take medications known to affect glucose tolerance
7. Subjects who have used insulin for diabetes or taken antihyperglycemic drugs
8. Subjects who have or are undergoing medical treatment for diseases which influence digestion and absorption of nutrients
9. Subjects who use or take "Foods for Specified Health Uses," or "Foods with Functional Claims" in daily
10. Subjects who currently taking medications (including herbal medicines) and supplements
11. Subjects who are allergic to medicines and/or the test food related products
12. Subjects who are pregnant, lactation, or planning to become pregnant
13. Subjects who suffer from COVID-19
14. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
15. Subjects who are judged inappropriate as subjects from answers to lifestyle questionnaires
16. Subjects who are shift workers or late-night shift workers
17. Subjects who are judged as ineligible to participate in the study by the physician
Target sample size
12
Research contact person
Name of lead principal investigator
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Organization
Medical Corporation Seishinkai, Takara Clinic
Division name
Director
Zip code
141-0022
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
TEL
03-5793-3623
t-takara@takara-clinic.com
Public contact
Name of contact person
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
Organization
ORTHOMEDICO Inc.
Division name
R&D Department
Zip code
112-0002
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL
03-3818-0610
Homepage URL
nao@orthomedico.jp
Sponsor or person
Institute
ORTHOMEDICO Inc.
Institute
Department
Personal name
Funding Source
Organization
Noster Inc.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic
Name of secondary funder(s)
IRB Contact (For public release)
Organization
the ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address
9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.
Tel
03-5793-3623
IRB@takara-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 05 | Month | 27 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
14
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2022 | Year | 05 | Month | 18 | Day |
Date of IRB
| 2022 | Year | 05 | Month | 18 | Day |
Anticipated trial start date
| 2022 | Year | 05 | Month | 26 | Day |
Last follow-up date
| 2022 | Year | 08 | Month | 07 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2022 | Year | 05 | Month | 27 | Day |
Last modified on
| 2022 | Year | 12 | Month | 23 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054581
